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Background: Radiolabeled annexin A5 (AnxA5) is widely used for detecting phosphatidylserine exposed on
cell surfaces during apoptosis. We describe here a newmethod for labeling AnxA5 and a size-matched control
protein with short-lived carbon-11, for probing the speciﬁcity of in vivo cell death monitoring using positron
emission tomography (PET) imaging.
Methods: AnxA5 and the control protein were recombinantly expressed with a C-terminal “Sel-tag”, the
tetrapeptide –Gly-Cys-Sec-Gly–COOH. The proteins were then labeled either ﬂuorescently for in vitro corrob-
orations of binding behaviors or with 11C for dynamic in vivo PET studies.
Results: AnxA5 demonstrated retained calcium-dependent binding to apoptotic cells after the C-terminus
modiﬁcation. The control protein showed no functional binding. The 11C-ligands demonstrated similar in
vivo pharmacokinetic behavior in healthy mice except for higher uptake in kidney and higher intact elimina-
tion to urine of AnxA5. After inducing hepatic apoptosis, however, the uptake of labeled AnxA5 in the
targeted tissue increased compared to baseline levels while that of the control protein tended to decrease.
Conclusions: These data suggest that the combined use of these two tracers can facilitate differentiating spe-
ciﬁc AnxA5 binding and its changes caused by induced cell death from uptake due to non-speciﬁc permeability
and retention effects at baseline or after therapy.
General signiﬁcance: The Sel-tag enables rapid and mild reactions with electrophilic agents giving site-speciﬁcally
labeled proteins formulti-probe analyses. The combined use of 11C-labeled AnxA5 and a size-matched control pro-
tein with dynamic PET can be useful for evaluating drug effects on target as well as off-target tissues.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Key issues for the successful optimization of personalized medical
care are the abilities to correctly diagnose the disease, to choose the
most appropriate therapy and to evaluate the therapeutic response —
all on an individual basis.Molecular imaging by positron or single photon
emission tomography (PET or SPECT, respectively) with nano- to
picomolar sensitivities can be used to non-invasively localize diseasedgy, PET Radiochemistry, R3:00,
eden. Tel.: +46 8 517 75331;
.Arner@ki.se (E.S.J. Arnér),
ND license.tissue based on its underlying biochemical features and to, over time,
monitor the effects of therapeutics directly in the diseased tissue [1–3].
New imaging tracers ranging from small molecules, to regulatory pep-
tides, proteins, antibody fractions and monoclonal antibodies are under
evaluation as diagnosticmolecular imaging biomarkers [4]. Furthermore,
polypeptide probes with high afﬁnity and selectivity for an increasing
number of targets are being selected by molecular display techniques
[5–7]. PET has typically used the small, rapidly equilibrating molecules
as tracers while the larger molecules have been used in SPECT imaging.
Intermediate-sized polypeptides may also clear fairly rapidly from the
circulation [8,9]. Properly labeled, they can therefore potentially be
used to visualize targets with relatively low background interference
very soon after administration. This may be desirable in many situations
and crucial when trying to observe rapidly progressing disease processes
(e.g. [10]). Finding an appropriate balance between tracer clearance
and delivery rates to target tissues can thus involve changing both the
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intended use. The labeling strategies neededmay therefore vary through-
out any tracer development and implementation process, suggesting a
need for the development of novel radiolabeling methodologies of pro-
teins for a range of different radionuclides.
Tracer substances for SPECT are labeled with long-lived (t1/2 hours–
days) radiometals and halogens. PET primarily uses short-lived (t1/2
2–110 min) “bioisotopes”, although more long-lived positron-emitting
radionuclides are also available [11,12]. Dynamic PET scanning with
shorter-lived nuclides can be used to study tracer pharmacokinetics,
to visualize multiple aspects that affect the delineation of diseased
tissue and to reveal overall as well as individual parametric effects
from therapy [13,14]. In the high throughput demands of clinical imag-
ing, however, both SPECT and PET more often rely upon longer-lived
radionuclides for “injecting outside the scanner, wait and then scan”
protocols. Multiple scans of a given individual will then require waiting
until the radiotracer has cleared and/or decayed, which may be up to
days depending on the radionuclide or its in vivo behavior. Further-
more, the dose exposures from retained, long-lived radionuclides may
become a limiting factor for repeated monitoring over time.
The short-lived PET radionuclides are not only a good match with
the typically rapid pharmacokinetics of smaller polypeptides, but are
also favorable for longitudinal studies. Though the use of 68Ga (t1/2
68 min) is growing with increasing availability of generators, the
most commonly used are 18F (t1/2 110 min) and 11C (t1/2 20 min),
which are produced many times daily by cyclotrons at PET research,
production and clinical imaging facilities. 18F is used in clinical PET
for snapshot imaging at discrete time-points and observations over
several hours, next-day repeated imaging and can be transported
within several hours from the production site. 11C gives generally
lower radiation doses and allows sequential tracer injections after
2–3 h (particularly important during validation phases and in clinical
research protocols when performing e.g. Scatchard analyses, drug
challenges to probe the speciﬁcity of new tracers, multi-tracer studies
to probe different biochemical features of the tissue or when moni-
toring rapid changes in target tissues).
Labeling polypeptides with 18F has been achieved using a number
of primarily amino- and thiol-reactive radiolabeling precursors, while
successful labeling with 11C has only been reported for a few proteins
that could tolerate either rather harsh labeling conditions or the
insertion of a radiolabeling tag at multiple and random labeling posi-
tions [15]. We have previously presented a method for rapidly, mildly
and site-speciﬁcally labeling proteins with 11C. This method is basedFig. 1. Proteins can be tagged in the C-terminus for subsequent labeling through the Sec res
teins, using introduction of a sequence encoding the Sel-tag at the 3′-end of the open readin
element in the mRNA with a 11 nt long stem and a loop region binding the E. coli SelB e
selenenylsulﬁde at the C-terminus of a Sel-tagged protein (left) and its reduction by DTT the
with electrophilic compounds for site-speciﬁc labeling. The ﬁgure shows the corresponding X
which natively carries the –Gly-Cys-Sec-Gly motif of the Sel-tag [59]. (C) Flow scheme foron the recombinant insertion of a tetrapeptide –Gly-Cys-Sec-Gly–
COOH motif, called a “Sel-tag” (ST) [16–18] at the C-terminus of a
protein (Fig. 1A). Upon its reduction, a highly nucleophilic sele-
nocysteine (Sec) residue (Fig. 1B) is exposed that can react with elec-
trophilic reagents. The method for Sel-tag based radiolabeling was
developed using several different proteins andwas recently also success-
fully utilized with a 6 kDa Afﬁbody molecule [19]. Using this Afﬁbody
molecule, excellent detection of lesions with over-expressions of HER2
was possible 30–60 min after i.v. tracer injection. Furthermore, spec-
iﬁcity of binding could be demonstrated in a second scan a few hours
later by pre-blocking with unlabeled protein in each individual
tumor-bearing mouse, thereby minimizing the inﬂuence of inter-
individual differences [19]. Here we hypothesized that this labeling
technique might also be utilized for PET imaging of even larger pro-
teins with appropriately rapid pharmacokinetics in vivo and where
a 11C-label could be advantageous for longitudinal studies. For this
study, we chose annexin A5 (AnxA5), which has often been evaluat-
ed for the detection of cell death, using a multitude of different label-
ing methodologies that may serve as benchmarks for the results of
our current approaches.
The ability to monitor cell death over time can be very important,
both for early detection of developing pathology and for making deci-
sions about therapeutic response in target tissues such as tumors
in order to avoid excessive systemic exposure to drugs with toxic
side-effects. Currently the most widely-used imaging biomarkers for
monitoring cell death are based on AnxA5. This endogenous 36 kDa
protein binds with high afﬁnity to phosphatidylserine (PS) which is
externalized from the cytosolic side to the surface of the cells when
they are dying (apoptotic) or dead (late apoptotic or necrotic) [20,21].
AnxA5 is characterized by very rapid initial blood clearance after intra-
venous (i.v.) administration [22,23]. The AnxA5-based tracers that have
been described typically show low target/non-target uptakes in animal
models as well as in patients and ﬁnding the optimal time for scanning
can therefore be difﬁcult [24]. Therapeutic monitoring with AnxA5
tracers needs baseline scanning as a reference point and incremental
changes in both positive and negative directions have been interpreted
as indications of drug efﬁcacy [20,25], even though it is expected that
increasing cell death would lead to increased tracer uptake. Enhanced
permeability and retention (EPR) effects in tumors caused by leaky ves-
sels and poor lymphatic drainage [26] can be deliberately used to en-
hance the deposition of macromolecular therapeutics [27,28], but can
also confound imaging results that are attempting to estimate the de-
gree and variations in binding interactions [29]. The contribution ofidue. (A) Scheme showing the principle for production of recombinant Sel-tagged pro-
g frame (ORF), followed by a bacterial-type selenocysteine insertion sequence (SECIS)
longation factor for Sec insertion (17). (B) Model of the inert oxidized Sel-tag with a
reby exposing the reactive selenolate of Sec (right), which subsequently can be targeted
-ray crystal structure of the C-terminus of oxidized and reduced thioredoxin reductase,
the syntheses of the labeled proteins.
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addressed.
We have in this study prepared Sel-tagged AnxA5 labeled with
the short-lived positron-emitting radionuclide 11C to enable multiple
dynamic PET imaging sessions in the same individual for probing fea-
tures of the tracer behavior. Both the C- and N-termini are on the op-
posite side of the AnxA5 molecule away from its membrane-binding
region, with the N-terminus helping to link domains I and IV and
being non-covalently located close to the C-terminus [30]. Therefore,
labeling at either the C- or N-terminus should minimally interfere
with the protein binding at target membranes, which however had
to be veriﬁed. To estimate tissue uptake due to non-speciﬁc per-
meability and retention (EPR) effects due to the size of 11C-labeled
Sel-tagged AnxA5 ([11C]-AnxA5-ST), a similar-sized 11C-labeled Sel-
tagged protein was also made. It was constructed of redox inactive
(Cys-to-Ser mutated) Escherichia coli thioredoxin (“mTrx”) fused at
its C-terminal end with green ﬂuorescent protein (GFP), which was
Sel-tagged at the C-terminus to give mTrx-GFP-ST. These two protein
domains are known to be globular and of high stability, but presumed
to lack inherent biological activity since they have no enzymatic
activities nor would they be naturally found in a mammalian host.
We reasoned that they would thus not likely target any speciﬁc mam-
malian receptors and as such be suitable for assessment of EPR effects
mainly due to size. We ﬁrst examined in vitro the binding capability
to apoptotic cells of the proteins, after ﬂuorescence labeling through
the Sel-tag. Subsequently, after 11C-labeling, we evaluated their in
vivo pharmacokinetics in healthy animals and compared their up-
takes in a conventionally used model of liver apoptosis as induced
with anti-fas antibodies [31]. The results obtained further illustrate
the versatility of the Sel-tag for radiolabeling proteins and demon-
strate that in vivo PET imaging of changes in the regional liver uptake
of [11C]-AnxA5-ST appropriately reﬂects the robust hepatic apoptosis
that was also conﬁrmed by ex vivo tissue analyses. Additionally,
changes in binding of [11C]-AnxA5-ST in tumor xenografts have
recently also been shown to visualize even moderate levels of cell
death as induced by single dose doxorubicin treatment, also corrobo-
rated by ex vivo tissue analyses and correlated with serum markers
of apoptosis in a separate study [32]. The present study further dem-
onstrates the characteristics and versatility of [11C]-AnxA5-ST as a
ligand for cell death detection using PET and also underscore that
characterization of EPR effects with a size-matched control ligand
may be utilized in studies of hepatic cell death.
2. Materials and methods
2.1. Materials
2.1.1. General
If not otherwise speciﬁed, all chemicals were obtained from Sigma-
Aldrich Chemical Corporation. Speciﬁc materials for the expression of
Sel-tagged proteins were previously described [16–18].
2.1.2. Expression and puriﬁcation of Sel-tagged proteins (Fig. 1A)
A plasmid encoding Sel-tagged AnxA5 was made by ﬁrst using
PCR with forward primer (Invitrogen): 5′-GGCATATGGCACAGGTTC
TCAGAGGC, and reverse primer: 5′-GGGGATCCGCCGCATAGGCTAAC
GATTGGTGCAGACCTGCAACCGATTATTAGCCTCAGCATCCGTCATCTTCT
CCACAGAGC using human AnxA5-encoding cDNA as template (OriGene
Technologies, Inc.). The PCR product was cloned into the NdeI-BamHI
sites of pET-15b (Novagen) and the construct was subsequently trans-
formed into a BL21(DE3) E. coli strain (Novagen), the N-terminal
His-tag from the vector itself was preserved in the construct. After veri-
ﬁcation of the construct by DNA sequencing (GATC biotech), the plasmid
pSUABC for improved Sec insertion was co-transformed into the same
host bacteria [33]. A single bacterial colony was inoculated into 1 l of
modiﬁed LB medium (10 g yeast extract, 10 g peptone and 10 g NaClper liter, pH 7.0) supplemented with 100 μg/ml ampicillin and 34 μg/ml
chloramphenicol for protein production. Prior to the induction of protein
expression, 100 μg/ml L-Cys and 5 mM selenite were added. Protein ex-
pression was induced with 1 mM isopropyl β-D-thiogalactopyranoside
at A600 of 2.4 for 16 h at 24 °C [17,34]. Cells were harvested by
centrifugation at 5000 g for 15 min, and the pellets were resuspended
in 50 ml PBS (phosphate buffered saline, pH 7.4, Gibco) supplemented
with 1 mg/ml lysozyme. The bacterial suspensions were sonicated and
clariﬁed by centrifugation at 13,000 g for 30 min. The Sel-tagged protein
can be speciﬁcally puriﬁed over phenylarsine oxide (PAO) sepharose
[16–18] but was here for the sake of ease puriﬁed using its His-tag.
Thus, for puriﬁcation of AnxA5-ST the bacterial lysate supernatants
were ﬁltered through a 0.22 μm ﬁlter and applied onto a 5-ml HisTrap
Crude FF column equipped on the ÄKTAExplorer 10 HPLC system
(GE Healthcare). The column was washed extensively with PBS buff-
er containing 50 mM imidazole, and the bound protein was eluted
with PBS buffer containing 250 mM imidazole. The eluted protein
was further puriﬁed on ÄKTAExplorer 10 HPLC system using a HiLoad
16/60 Superdex 200 pg gel ﬁltration column (GE Healthcare) and
simultaneously the protein sample was desalted with a change to PBS
buffer. Subsequently, the protein was concentrated by ultraﬁltration
using a 30-kDa cut off ultracentrifuge device (PALL) and the ﬁnal pro-
tein concentration was determined spectrophotometrically (280 nm)
using a calculated molar extinction coefﬁcient of 21,050 (M−1 cm−1).
Protein integrity was also checked by His-tag western blot using
SuperSignal West HisProbe Kit (Thermo). Upon protein puriﬁcation,
we also included a thoroughwash of the nickel columnusing 50 column
volumes of 0.1% triton X-114 before eluting the protein with imidazole,
in order to remove endotoxin from the protein sample [35]. The endo-
toxin levels of different stock solutions were analyzed by Karolinska
Pharmacy according to the methods in European Pharmacopoeia and
found to be below limits of detection (b2.5 IU/ml).
The control protein for EPR effects was designed as the globular
and stable E. coli protein thioredoxin made redox inactive with its
two active site Cys residues changed to Ser, fused with the other glob-
ular protein green ﬂuorescent protein, which was Sel-tagged yielding
mTrx-GFP-ST. The plasmid encoding this protein was constructed by
ﬁrst utilizing a cDNA for GFP obtained from the pGFPuv plasmid
(Clontech). To facilitate the downstream cloning procedure, an inter-
nal NdeI site (CATATG) within the ORF of GFP was silently mutated
to CACATG on the original vector by enzymatic inverse PCR [36]
using forward primer 5′-GTGGTCTCCACATGAAACGGCATGACTTTTT
CAAG and reverse primer 5′-GTGGTCTCCATGTGATCCGGATAACGGG
AAAAGC. The new GFP ORF was cloned into the NdeI–NotI sites
of pET-20b using forward primer 5′-GGCATATGAGTAAAGGAGAAG
and reverse primer 5′-GTGCGGCCGCATAGGCTAACGATTGGTGCAGA
CCTGCAACCGATTATTAGCCTCAGCATCCTTTGTAGAGCTCATCCATG. An
N-terminal His tag was introduced into this construct by inverse
PCR with forward primer 5′-GTGGTCTCCCATGGGCCATCATCATCATC
ACCATATGAGTAAAGGAGAAGAAC and reverse primer 5′-GCGGTCT
CCCATGGTATATCTCCTTCTTAAAGTTAAAC. This construct produced
GFP with a C-terminal Sel-tag (named GFP-ST). To fuse the Sel-
tagged GFP domain with another globular protein in order to reach
a similar size as AnxA5, we used a cDNA for E. coli thioredoxin (Trx)
as obtained from the pET32a plasmid (Novagen) by single NdeI diges-
tion. The E. coli Trx-encoding fragment was then cloned into the con-
struct of GFP-ST at the NdeI site located between the N-terminal
His-tag and the GFP open reading frame. This construct thus encoded
a fusion protein, wtTrx-GFP, with a Sel-tag at its C-terminus
(wtTrx-GFP-ST). Finally, in order to avoid any redox activity of this
protein, the two Trx-derived catalytic active site Cys residues (C32
and C35) of ST-wtTrx-GFP were mutated to Ser by inverse PCR
using forward primer 5′-GTGGTCTCGGTCCGAGCAAAATGATCGCCC
CGATTC and reverse primer 5′-GTGGTCTCCGGACCGCTCCACTCTGCCC
AGAAATCG, which resulted in the ﬁnal construct used in this study,
mTrx-GFP-ST.
Fig. 2. Fluorescence of AnxA5-ST and mTrx-GFP-ST after labeling with 5-IAF. In (A) the
inherent ﬂuorescence under UV illumination is shown for native Sel-tagged AnxA5
(AnxA5-ST), the same after ﬂuorescent labeling with 5-IAF ([AF]-AnxA5-ST), the
size-matched control (mTrx-GFP-ST) and the same protein after labeling with 5-IAF
([AF]-mTrx-GFP-ST). All four proteins are in cuvettes and 1.5 mg/ml in PBS. Note that,
due to the inherent ﬂuorescence of its GFP domain, mTrx-GFP-ST is ﬂuorescent prior
to labeling with 5-IAF. In (B) the same samples separated on SDS-PAGE (in the same
order as in (A)) with ﬂuorescence are visualized on a UV table using the non-stained
gel. Note that mTrx-GFP lost its inherent ﬂuorescence as a result of denaturing con-
ditions whereas the ﬂuorescein tag was still ﬂuorescent in both of the 5-IAF labeled
proteins. In (C) the same gel as in (B) was stained with Coommassie. The sizes (kDa)
of molecular weight markers are shown to the left of the gels in (B) and (C).
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2.2.1. Fluorescence labeling
The AnxA5-ST or mTrx-GFP-ST (5 mg/ml in 100 μl PBS) was re-
duced with 2 mM DTT for 20 min at room temperature, followed by
addition of 5 mM 5-iodoacetamidoﬂuorescein (5-IAF, Invitrogen,
dissolved in DMSO) and incubation for 20 min at room temperature.
The ﬂuorescently labeled proteins, [AF]-AnxA5-ST or [AF]-mTrx-GFP-
AF, were desalted on a NAP-5 column (GE Healthcare) and further
puriﬁed on ÄKTAExplorer 10 HPLC system using Superdex 200 10/
300 GL gel ﬁltration column and PBS pH 7.4 as mobile phase. The
purity and ﬂuorescence of the proteins were conﬁrmed by SDS-PAGE
with UV irradiation and Coomassie staining [16–18] (Fig. 2).
2.2.2. Radiolabeling with positron-emitting [11C]CH3I
[11C]Methane was prepared by the proton irradiation of a N2/H2
gas mixture in the 14N(p,α) 11C reaction and using a PETtrace cyclo-
tron (GE Healthcare). [11C]Methane was converted to [11C]CH3I
using iodine in a gas phase reaction [37] using an automated synthe-
sis module, Tracerlab FX C Pro (GE Healthcare) and trapped at room
temperature in DMSO (0.20 ml). Sel-tagged protein (450 μl, 5 mg/ml)
was reduced with 2 mM DTT for ≥20 min at room temperature,
followed by the addition of an aliquot (50 μl) of the [11C]CH3I solution.
Immediately after the 20–25 min incubation at 35–37 °C, the sample
was desalted over a NAP-5 column pre-equilibrated with PBS free
from divalent cations. An aliquot of the eluted protein fraction
(0.4 ml) was dispensed in sterile syringes and diluted with saline
to 0.2 ml for immediate injections in the animals. The efﬁcient removal
of other radiolabeling reagents and side-products was conﬁrmed and
the radiochemical purity of the preparation was routinely examined
using a Superdex 75 10/300 GL gel ﬁltration column (GE Healthcare)
eluted with PBS pH 7.4 on an HPLC equipped with both UV (210 nm)
and radioactivity detectors (Fig. 3).
2.3. In vitro analyses of protein functionality
2.3.1. Cell culturing
Adherently growing FaDu (squamous cell carcinoma), obtained
from ATCC, were cultured in Dulbecco's modiﬁed eagle medium
(DMEM) GlutaMax (Invitrogen) supplemented with 0.1 mM non-
essential amino acids, 10% fetal bovine serum (FBS), 1 mM sodium
pyruvate, 100 units penicillin/ml, 10 μg streptomycin/ml and 2 mM
HEPES. U266 (myeloma) cells, kindly provided by Prof. Dan Grandér,
Karolinska Institutet, Sweden, were grown in suspension in RPMI
medium (Sigma Aldrich) supplemented with 10% FBS, 100 units
penicillin/ml and 10 μg streptomycin/ml. Both were incubated at
37 °C and 5% CO2 in a humidiﬁed environment. The integrity of the
U266 and FaDu cell lines was veriﬁed in 2009 and 2010, respectively,
with STR proﬁling cell authentication analysis (LGC standards).
2.3.2. Binding to apoptotic cells in culture
FaDu cells were seeded at a density of 100 000 cells/well in
24-well plates 24 h prior to treatment with 2 μg/μl anti-mouse Fas
(BD Pharmingen) for 48 h. After treatment, cells were washed with
PBS and AnxA5 binding buffer (taken from the FITC AnxA5 apoptosis
detection kit 556547, BD Pharmingen) before incubation with either
0.5 μg/ml [AF]-AnxA5-ST or [AF]-mTrx-GFP-ST (resuspended in AnxA5
binding buffer) for 20 min at 37 °C. Finally the cells were washed with
1× PBS and incubated 5 min with 0.5 μg/ml propidium iodide solution
(PI) (BD Pharmingen). Fluorescence microscopy images were taken
using a Zeiss AxioVert 40 CFL microscope.
2.3.3. Flow cytometry
U266 cells were treated with 1 μM b-AP15 [38] for 14 h. Flow cy-
tometry assays were performed with treated or untreated U266 cells
at 2×105 cells/plate with 1 μg/ml ﬁnal concentration of [AF]-AnxA5-ST
Fig. 3. AnxA5-ST is radiolabeled using [11C]-CH3I and rapidly puriﬁed by gel ﬁltration.
(A) The reaction of AnxA5-ST with [11C]-CH3I after 20 min at 35 °C gave≈30% conver-
sions as analyzed by radio-HPLC (top UV trace and bottom radioactivity trace, radioac-
tivity traces shown are corrected post-analysis for decay). (B) The protein after NAP-5
gel ﬁltration was >99% radiochemically pure. Retention times=10, 11.5 and 32 min
for the dimer, [11C]-AnxA5-ST and [11C]-methyl iodide, respectively.
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of 10 mM HEPES-Na, pH 7.4, 130 mM NaCl, 4 mM KCl, 0.9 mMMgCl2,
0.8 mM NaH2PO4, 5 mM glucose, 1.0 mg/ml BSA, and CaCl2 varying
from 0 to 3.0 mM. After incubation in the dark at 25 °C for 10 min in
the presence of 5 μg propidium iodide to distinguish apoptotic from ne-
crotic cells, analysis was performed by ﬂow cytometry with a 488 nm
laser. The cells were delineated with forward and side-scatter gating
and apoptotic cells were identiﬁed as AnxA5-positive and PI-negative.
2.3.4. Cell binding assay
The membrane-binding afﬁnity of [AF]-AnxA5-ST utilizing calci-
um titration assay with red blood cells was determined as described
[39]. Brieﬂy, preserved human red blood cells (RBC) were obtained
from Beckman Coulter (COULTER® 4C® Plus Cell Control) and the
cells were stored at room temperature for two weeks in order to
fully expose the PS on all RBC's. Analytical calcium chloride solution
was obtained from Sigma. The reactions were prepared with addition
of 1 nM [AF]-AnxA5-ST and 1×108 RBC into 1 ml calcium titration
assay buffer of 50 mM HEPES (pH 7.4), 100 mM NaCl, 0.02% NaN3
and 1 mg/ml BSA with various CaCl2 supplements (0, 0.6, 0.9, 1.0,
1.2, 1.4, 1.6, 2.0, 2.2, 2.6, 3.0, 3.5, 5.0, 7.0 mM), respectively. Eachreaction was duplicated and took 8 min at room temperature. Sub-
sequently the unbound [AF]-AnxA5-ST was removed from RBC by
centrifugation (3 min at 10,000 rpm) and the RBC was further washed
by assay buffer containing the same content of CaCl2 corresponding to
each reaction. Lastly, the bound [AF]-AnxA5-ST was released from RBC
by assay buffer containing 5 mMEDTA. After centrifugation, theﬂuores-
cence in the supernatant was determined by EnSpire®Multimode Plate
Reader (PerkinElmer) (excitation at 494 nm, emission at 518 nm).
2.4. In vivo preclinical PET imaging
2.4.1. Animal handling
All animal handling and experiments were carried out in accor-
dance with the guidelines of the Karolinska Institutet and were
approved by the local laboratory animal ethics committee. BALB/c
mice weighing 17–31 g were used in the studies. The animals were
housed under standard laboratory conditions with food and water ad
libitum and were transported to the microPET facility on the morning
of the experiments (at least 2 h prior to the experiments).
2.4.2. PET scanning procedures
Mice were anesthetized with isoﬂurane (initially 5% then 1.5%
blendedwith 3:2 air/O2), controlled by an E–Z anesthesia vaporizer de-
livered through individual Microﬂex non-rebreathingmasks (Euthanex
Corporation, Palmer, PA). They were placed on a heating pad (37 °C)
on the bed of the microPET Focus 120 camera (CTI Concorde
Microsystems). The PET tracer in a maximum volume of 0.2 ml was
injected via the tail vein. After the ﬁnal experiment the animals
were euthanized by cervical dislocation under continued anesthesia.
For imaging induced cell death in mouse liver, baseline uptake of
[11C]-AnxA5-ST or [11C]-mTrx-GFP-ST was ﬁrst determined in 1 h
microPET scans of BALB/c mice as described above. Ninety minutes
after the ﬁrst injection, liver apoptosis was induced by the intravenous
injection of anti-mouse Fas/CD 95 antibody (10 μg/animal, clone Jo2, BD
Biosciences). Two hours later, radiolabeled protein was again injected
and the mice were scanned for an additional 1 h. All animals survived
the entire procedure until immediately after the end of the second
scan, when they were euthanized and tissue samples were collected
post-mortem for immunohistochemical (IHC) analyses.
2.4.3. PET data collection and analysis
PET-data were acquired every second in fully three-dimensional
(3D) mode and images were reconstructed by standard 2D ﬁltered
back projection using a ramp ﬁlter. Data were processed withMicroPET
Manager and evaluated using Inveon Research Workplace (Siemens
Medical Solutions) software. Data were corrected for dead time, decay
and randoms. To determine the temporal changes of tracer concentra-
tions, regions of interest (ROIs) were drawn on the images after verify-
ing the anatomic localization of the organ of interest. For each organ
a standard volume of interest was drawn on images summed over
the same time frames. Radioactivity concentrations (Bq per milliliter)
were calculated automatically by calibrating against a phantom with
a known concentration of radioactivity. Assuming a tissue density of
1 g/ml, the radioactivity concentrations were divided by the adminis-
tered activity to obtain a ROI-derived percent injected dose per gram
of tissue (%ID/g). For comparisons between different individuals, nor-
malization to the same body weight was performed.
Data were further analyzed by the graphical method developed by
Logan et al. (see [40] and references therein) in combination with the
“Simpliﬁed Reference Tissue Model” [41]. A reference region on the
quadriceps was drawn and radioactivity concentrations calculated
as above. When ﬁtting a function of the ROI to a function of the refer-
ence region, the resulting slope of the curve gives the distribution vol-
ume ratio (DVR). By subtracting 1 from the DVR, the binding potential
is generated [42], a quantity that is a direct indication of the binding
in the ROI. When analyzed as ratios, compensation against systematic
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2.5. Ex vivo analyses
2.5.1. Radioligand metabolism during the PET scanning
Urine, plasma and blood samples were obtained upon euthanasia
at 20 or 40 min after i.v. injection of 11C-labeled protein in the anes-
thetized mice. To investigate the degradation and excretion of 11C-
labeled radiometabolites, the proteins in urine and plasma samples
collected post-mortem were precipitated by immediately adding 1 ml
pre-chilled acetone (-20 °C) to each sample (30–100 μl, depending on
the availability from the animals) and then storing at −20 °C for at
least 20 min. Insoluble and soluble fractions were subsequently sepa-
rated by centrifugation (14,000 rpm, 10 min) and the radioactivity of
each fraction was thereafter measured using a gamma counter (1480
Wizard 3″, Perkin Elmer, MA). For controls, samples containing only
puriﬁed radioactive protein or only radioactive low molecular weight
compounds were used, following the same handling procedures. From
separate animals, urine was also collected post-mortem and analyzed
by size-exclusion radio-HPLC with gamma counting of collected frac-
tions and by SDS-PAGE and Western blot.
2.5.2. Immunohistochemical analyses
Tissueswere resected,ﬁxed in 2%buffered formaldehyde, dehydrated,
embedded in parafﬁn and sectioned. Sections were deparafﬁnized with
xylene, rehydrated, microwaved and then incubated overnight with
monoclonal primary antibodies diluted in 1% (wt/vol) bovine serumalbu-
min and visualized using the standard avidin–biotin–peroxidase complex
technique (Vector Laboratories, Burlingame, CA, USA). Counterstaining
was performed with Mayer's haematoxylin. Antibody against active
caspase-3 was from Pharmingen and used at 1:1000.
3. Results
3.1. Sel-tagged AnxA5 and mTrx-GFP can be produced by recombinant
expression
The puriﬁed recombinant proteins were typically obtained at a
yield of 10–20 mg per liter of bacterial culture as mixtures of UGA-
truncated and Sec-containing full-length proteins, as described [17].
Sec insertion at a single predeﬁned UGA codon was enabled by an
engineered SECIS element (Fig. 1A) and was conﬁrmed in separate
experiments by labeling with 75Se, using methodology described pre-
viously [17]. The Sec content in the protein preparations used in
the subsequent imaging experiments was estimated to be 20–30%,
based on previous use of this recombinant selenoprotein production
methodology [16–18]. Endotoxin levels were below detection limits.
The proteinswere stored in PBS at−20 °C. Dimerization or aggregation
(10–35%) occurred during long-term storage but was reversed by incu-
bating the protein with excess DTT at 35 °C followed by NAP5 puriﬁca-
tion just prior to the labeling experiments.
3.2. AnxA5 and mTrx-GFP can be ﬂuorescently labeled through the
Sel-tag and [AF]-AnxA5-ST detects apoptosis in vitro
To examine the ability of AnxA5-ST (but not of the control mTrx-
GFP-ST) after C-terminus modiﬁcation to bind to apoptotic cells, the
Sel-tagged proteins were reacted through the Sec residue with the
electrophilic ﬂuorescein derivative 5-IAF and their molecular weights
and ﬂuorescence conﬁrmed (Figs. 1C and 2). For the in vitro analyses,
cells were treated by two different agents shown to induce robust
apoptosis and binding was examined by microscopy and ﬂow cytom-
etry. Binding of [AF-AnxA5-ST] to FaDu cells treated with anti-Fas
antibodies was demonstrated (Fig. 4A). Positive cells displayed main-
tained cell membrane integrity, as illustrated by the lack of uptake ofpropidium iodide, and only a few cells in the untreated controls were
labeled. In contrast, ﬂuorescently labeled mTrx-GFP-ST displayed no
binding to apoptotic cells (Fig. 4A).
AnxA5 requires calcium for binding to PS-containing membranes.
The physiological concentration of ionized calcium is ~1.2 mM in
whole blood, but may be lower in tumor tissue as discussed in
[43]. To verify that the C-terminal modiﬁcation did not affect the
calcium-dependency of the protein binding, AF-labeled AnxA5-ST or
commercially available FITC-labeled AnxA5 were added to apoptotic
U266 cells at different calcium concentrations and binding was
quantiﬁed using ﬂow cytometry (Fig. 4B). Both [AF]-AnxA5-ST and
FITC-labeled AnxA5 demonstrated calcium dependent binding. The
lower degree of binding found for the FITC-AnxA5 is consistent with
its random labeling, which has been shown to reduce the PS binding
of other AnxA5 probes [44]. Importantly, binding of [AF]-AnxA5-ST to
apoptotic cells was observed at calcium concentrations as low as
0.5 mM, concentrations sometimes found in tumors.
Furthermore, the effect of C-terminus modiﬁcation on the binding
afﬁnity of [AF]-AnxA5-ST was examined using the calcium titration
aged RBC binding assay at low membrane occupancy b1% (low pro-
tein concentration) [39]. The EC50 and the slope are determined
from the titration curve in Fig. 5. The negative log of the binding con-
stant, pK, was calculated with
pK ¼− nlogEC50þ log Membrane½ ð Þ
with
n the Hill slope
EC50 molarity of Ca2+ at which cell binding is half the maximun
value
[Membrane] concentration of annexin A5 binding sites in the assay,
estimated as 180 nM according to [39].
The EC50 was 1.463±0.014 mM, the Hill slope was 6.784±0.411
and the calculated pK was 26.0. This pk value is in the same range as
for previously reported variants tested with this assay. The pk for
[AF]-AnxA5-ST was lower than that reported for Anx V-128 (pK=
30.8), but higher than that of the clinically used 99Tcm-MAG3-AnxA5
(pK=23.1) and 99Tcm-HYNIC-AnxA5 (pK=21.3) as well as that of the
mutants purposefully modiﬁed in the AnxA5 binding sites, V-131,
V-138, V-136 and V-139 (pK values of 22.4, 22.4, 13.9 and 15.8, respec-
tively) [45]. These data indicate that, as predicted by the structural data,
the C-terminus of AnxA5 can bemodiﬁed for labeling without seriously
interfering with its four Ca2+ binding sites.
3.3. AnxA5 and mTrx-GFP can be 11C-labeled through the Sel-tag
We next utilized the Sel-tag for 11C-labeling for the use of the
proteins in PET imaging. As previously observed with other proteins
[16], the labeling yields increased with increasing amounts of protein,
time and temperature (room temperature to 35 °C). Conditions were
sought that minimized the use of the protein starting material since
[11C]CH3I could be produced in amounts far greater than what was
needed for the intended applications. Under the 11C-labeling con-
ditions subsequently employed in these PET experiments, 10–30%
decay-corrected conversions of the added [11C]CH3I were obtained.
The preparation of [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST required
30 min (≈1.5 11C half-lives) from the end of [11C]CH3I production
and the isolated proteins were sufﬁciently radiochemically pure for
in vivo studies (Fig. 3). Effective speciﬁc radioactivity was 5000–
10,000 MBq/μmol, based on the total unlabeled protein used in the
labeling reactions. On the order of 1 nmol protein was typically used
in the PET studies.
Fig. 4. AnxA5-ST but not mTrx-GFP-ST binds to apoptotic cells in a Ca2+ dependent fashion. (A) Adherently growing FaDu cells were treated with anti-Fas antibodies and incubated
with ﬂuorescent (green) [AF]-AnxA5-ST or [AF]-mTrx-GFP together with PI (red). In the top row two ﬁelds of view with [AF]-AnxA5-ST and one with [AF]-mTrx-GFP-ST are shown,
with the corresponding light microscopy images in the row below. [AF]-AnxA5-ST bound early apoptotic cells with maintained membrane integrity (green cells, no PI uptake) and
late apoptotic or necrotic cells (green and red). Some isolated nuclei only binding PI (solely red stained) are also seen. In contrast, incubations with [AF]-mTrx-GFP-ST revealed the
control protein did not bind the apoptotic cells (no green cells) and only red PI-stained nuclei were detected. (B) U266 cells, grown in suspension and treated with b-AP15 [38] to
induce apoptosis, were used in ﬂow cytometry analyses of the Ca2+ dependency of the binding of tagged AnxA5. The fraction of apoptotic cells (AnxA5-binding to PI-negative cells)
detected by [AF]-AnxA5-ST (ﬁlled squares) varied with Ca2+ concentration in a similar way as that of commercially available standard FITC-annexin V (open squares). Data are
means±SEM. The curves are nonlinear regression ﬁts of the data using the “binding — saturation (one site — speciﬁc binding)” function (Prism).
2568 Q. Cheng et al. / Biochimica et Biophysica Acta 1830 (2013) 2562–25733.4. 11C-Labeled AnxA5-ST and its size-matched mTrx-GFP have similar
behavior in vivo except in the kidney and urine
The distribution of [11C]-AnxA5-ST in a healthy mouse at different
time intervals after tail vein injection is illustrated in Fig. 6A. The
kinetics of distribution of [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST
are shown in the time–activity curves for the kidney, liver and muscle
in Fig. 6B and C and for arterial blood in Fig. 6D averaged for two mice
in which paired tracer imaging studies were performed. After the ini-
tial rapid decrease in the ﬁrst 10 min, radioactivity subsequently
cleared more slowly from the blood after 20 min with t1/2 of 37 and
28 min for [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST to levels of 6.0
and 5.2%ID/g at 60 min, respectively. Radioactivity in the liver peakeddirectly after injection, decreased until around 10 min and thereafter
increased again to about 11% ID/g at 48 min. Uptake in skeletal muscle
(used as a reference region in subsequent analyses) was similar for
the two tracers and increased slightly throughout the scan. The highest
initial radioactivity concentrationswere in the kidneys, reaching amax-
imum at 10 min and subsequently steadily decreasing concomitant
with an increase in the urinary bladder, which could be detected as
early as 2–5 min after tracer administration. By the end of the 1 h
scan 5–10% of the total injected dose was in the urine. Although the
renal time activity curves followed the same general pattern, [11C]-
AnxA5-ST peaked at a higher value than that of [11C]-mTrx-GFP-ST
and was 43% higher at the end of the scan. The intra-subject differences
were also observed in inter-subject (n=4) comparisons, with the only
Fig. 5. Titration of [AF]-AnxA5-ST binding to PS-enriched membranes with varying
calcium concentrations according to the method in [39]. The net counts of each reading
were normalized by the maximum reading. A nonlinear regression ﬁt was generated
by GraphPad Prism software (one site — speciﬁc binding with Hill slope). The EC50
is 1.463±0.014 mM and the hill slope (n) is 6.784±0.411 and the PS binding sites
([Membrane]) in the assay is estimated as 180 nM according to [39]. The negative
log of the binding constant, pK, calculated from the slope and EC50 is 26.0.
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Differences in ﬁnal distribution volume ratios (Fig. 6F) gave higher
binding potentials in kidney for [11C]-AnxA5-ST than for [11C]-mTrx-
GFP-ST, (12.0±1.3 and 7.0±1.5, respectively, pb0.03 for 95% CI),
which we believe reﬂects a speciﬁc renal uptake of the annexin-based
radiotracer.
Analyses of post-mortem samples after studies with [11C]-AnxA5-
ST (n=4) indicated that a majority of the radioactivity in plasma
and whole blood remained in high molecular weight form (Fig. 7A).
Similar proportions were observed for [11C]-mTrx-GFP-ST (Supple-
mentary Fig. 1A). However, a fairly large proportion (35–45%) of
high molecular weight radioactivity was also observed in the urine for
[11C]-AnxA5-ST but not for [11C]-mTrx-GFP-ST. Subsequent radio
HPLC analyses of the urine of animals scanned with [11C]-AnxA5-ST re-
vealed a peak with the same retention time as the intact radiolabeled
protein (Supplementary Fig. 1B). Analyses by SDS-PAGE and Western
blot conﬁrmed the presence of a ≈35 kDa protein, apparently intact
AnxA5 (Fig. 7B). No such band was found in the analyses of urine
from animals receiving other tracers.
Analyses of the radioactivity in the entire mouse body throughout
the PET scan consistently indicated a loss of up to 10–20% of the
injected dose for both 11C-labeled proteins. A potential explanation
for this observation could be a loss of volatile, labeled metabolites
through exhalation.
3.5. [11C]-AnxA5-ST binding but not that of [11C]-mTrx-GFP increases in
apoptotic mouse liver
[11C]-AnxA5-ST readily visualized induced liver apoptosis in vivo
(Fig. 8A), consistent with previous functional validations of other
AnxA5-based radioligands [46,47]. Following the i.v. injection of
[11C]-AnxA5-ST beginning at≈2 h after treatment with anti-Fas anti-
body, hepatic radioactivity concentrations increased to a maximum at
20 min and then slowly decreased to a plateau at 60 min. Levels were
four- and two-fold higher, respectively, than in the untreated livers at
the same time, indicating that robust read-outs for hepatic cell death
can be obtained as early as 20–30 min after tracer injection. The
increases were clearly seen in the normalized time activity curves
(Fig. 8B) as well as in the increases in distribution volume ratios
shown graphically in a Logan plot (Fig. 8C). IHC staining of active
caspase-3 in excised liver sections conﬁrmed extensive apoptosis in
the treated but not in the control mice (Fig. 8D). Similar experiments
using [11C]-mTrx-GFP-ST showed, in contrast, a tendency to a decrease
in concentrations of radioactivity and distribution volume ratios in theliver after anti-Fas treatment (Fig. 8E–G). The uptake of both [11C]-
AnxA5-ST and [11C]-mTrx-GFP-ST in the kidney decreased compared
to baseline after treatment with anti-Fas antibody to essentially the
same levels.
4. Discussion
We demonstrate here that AnxA5 labeled with the short-lived
isotope 11C through a Sel-tag can be used for rapid PET imaging of in-
duced cell death and that an identically-labeled, size-matched control
can be used for estimating the uptake due to permeability and reten-
tion effects related to the size of the protein probe. These tracers were
based on monomeric≈36-kDa proteins that had been recombinantly
expressed with a C-terminal Sel-tag and, to obtain the PET tracers, the
selenenylsulﬁde bridge was reduced with DTT to expose the reactive
selenolate for immediate reaction with [11C]CH3I. This protocol for
radiolabeling was developed previously by us [17] and it was also
shown that the reactivity of selenocysteine utilized in the rapid
radiolabeling protocol cannot be replicated with a cysteine residue
[16]. When utilized with a Sel-tag following our protocol, the radiola-
bel is covalent, residue-speciﬁc and, as shown here, suitable for use in
PET imaging. We also found here that Sel-tagged AnxA5 could be used
to detect apoptotic cells both in vitro in cell cultures and with ﬂow
cytometry after ﬂuorescence labeling, and in vivo with PET after 11C-
labeling, which demonstrates the versatility of the tagging method-
ology. The use of the short-lived 11C radionuclide allows same-day
intra-individual in vivo studies either with different tracers, or with
the same tracer prior to and after the induction of cell death. Combined
with dynamic PET imaging, several notable aspects concerning AnxA5
uptake in normal and pathological tissue were observed.
Radioactivity from both [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST
cleared fairly rapidly from the blood and was predominantly renally
eliminated, similar to other previously characterized AnxA5-based
imaging probes [21,48]. However, the 11C-labeled tracers showed a
much lower renal radioactivity retention than that seen with most
of the radiometal-labeled AnxA5 probes, a characteristic that has pre-
viously made visualization of paranephric structures difﬁcult [21,49].
Here, the renal uptake of [11C]-AnxA5-ST was 10% of that reported
for 99mTc-hydrazinonicotinamide (HYNIC)-annexin V in Balb/c mice
[47] and on the same low level as that achieved for the improved
99mTc-labeled annexin V-128 [44]. The uptake of the radiometal-
labeled AnxA5 ligands has been attributed both to higher levels of
PS in the renal cortex and medulla [47,50] and to relatively unspeciﬁc
retentions of the end products of the metabolism of the radiolabeled
polypeptide [44,47]. In our direct comparison with the size-matched
and identically labeled [11C]-mTrx-GFP-ST, a consistent difference
in the renal uptake of the two proteins in healthy mice throughout
the scans was observed, with a nearly 1.5-fold difference in their cal-
culated binding potentials. Since binding of AnxA5 in normal renal
tissue has been reported with levels that may vary with renal disor-
ders [51], we suggest that further studies validating the use of paired
imaging of [11C]-AnxA5-ST with [11C]-mTrx-GFP-ST, possibly also in
comparison with blocking experiments with the unlabeled protein as
successfully performed in [52], to estimate the speciﬁcity and degree
of binding of AnxA5 in the kidney and other tissues are warranted.
Our observation that intact [11C]-AnxA5-ST, but not [11C]-mTrx-
GFP-ST was secreted to the urine is consistent with prior reports
that intact AnxA5 can be found in the urine of the normal mouse
and can furthermore increase up to 40-fold during nephritis [51,53].
Since acute nephritis may be a side effect of some drugs, therapeutic
monitoring with radiolabeled AnxA5 should include evaluations of
drug effects on the tracer's renal uptake and elimination. Dynamic
whole body imaging in mice with [11C]-AnxA5-ST and [11C]-mTrx-
GFP-ST could provide the tools for more comprehensively evaluating
contributions of these factors to size of individual therapeutic read-
outs, particularly when validating new drug efﬁcacy analyses.
Fig. 6. [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST display similar kinetics in normal tissues in vivo. (A) Maximum intensity projection (MIP) images of radioactivity summed over
0–1 min, 1–5 min, 5–15 min, 20–35 min and 35–45 min after the injection of [11C]-AnxA5-ST at time zero in the tail vein of a mouse, demonstrating accumulation in urinary blad-
der after transient passage in heart and secretion through kidney. (B,C) Time activity curves for radioactivity in the kidney (diamonds), liver (squares) and muscle (circles) after tail
vein injection of [11C]-AnxA5-ST (ﬁlled symbols) and [11C]-mTrx-GFP-ST (open symbols) in two animals in which paired tracer imaging studies were performed. Curves are aver-
ages of the two animals and error bars are the standard deviations of the normal distributions of radioactivity. (D) Time activity curves showing similar clearance of radioactivity
from arterial blood after injection of [11C]-AnxA5-ST and [11C]-ST-mTrx-GFP-ST in the same two animals. (E) Biodistribution of [11C]-AnxA5-ST (ﬁlled bars) and [11C]-ST-mTrx-
GFP-ST (open bars) at 1 h after injection (means±S.D. n=4 in each group). Statistical signiﬁcance (p=0.028) only for differences in the kidney for the two tracers. (F) Logan
plots showing differences in distribution volume for [11C]-ST-AnxA5 (solid line) and [11C]-ST-mTrx-GFP-ST (dashed line).
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apoptosis [31], has been used previously for demonstrating the capa-
bility of radiolabeled AnxA5 probes to detect massive cell death in
vivo [46,47]. Similar to other radiolabeled AnxA5 probes, the [11C]-
AnxA5-ST levels increased after anti-Fas treatment, here up to four-
fold higher than baseline depending on the time at which the com-
parison was made. However, the uptake of [11C]-mTrx-GFP-ST tended
to decrease during the same period. This is in sharp contrast to theincreases in uptake of 125I-labeled human serum albumin after
anti-Fas treatments that were interpreted to be due to an expanded
extracellular ﬂuid volume from breakdown of hepatic endothelial
cells [47]. Anti-Fas treatment eventually causes gross injury with
focal hemorrhaging and necrosis, secondary to the massive apoptosis
[31]. Molecular size is a very important parameter affecting the rate
of uptake and degree of retention of macromolecules, particularly in
tissues with challenged circulation [29]. Albumin is nearly twice the
Fig. 7. [11C]-AnxA5-ST is rather stable in plasma and is secreted to urine. (A) Radioactivity
in the high-molecular weight fraction of [11C]-AnxA5-ST in blood, plasma and urine from 4
animals (means±SD) after either 20 min (solid bars) or 40 min (striped bars) as deter-
mined using acetone precipitation. (B) Coomassie stained SDS-PAGE (left) and Western
blot analyses (right) of urine from two mice injected with [11C]-AnxA5-ST (lanes 1 and 2)
and one control mouse without i.v. injection of [11C]-AnxA5-ST (lane 3). Recombinant
AnxA5-ST is shown as comparison in lane 4 and positions of molecular weight markers
(kDa) are indicated to the left.
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for which the liver expresses speciﬁc receptors [54]. Variations in
these levels could also contribute to the uptake of the tracer.
Mutants of AnxA5 [55] have been ﬂuorescently labeled and used
as control proteins in previous elegant studies of the transient nature
of PS exposure and its internalization after AnxA5 binding at discrete
times [56]. Such controls, having the same amino acid composition as
AnxA5, could potentially be used to examine the effects of e.g. size, li-
pophilicity and charge, all of which affect the kinetics of distributions
of ligands. However, native AnxA5 as well as the mutants also interact
by several means with cell membranes apart from PS-interaction,
with e.g. cytosolic phospholipase A2 [55], and it might thus be compli-
cated to identify and separate contributions of membrane binding
interactions on the pharmacokinetic behavior of the proteins from
EPR effects. Our use of mTrx-GFP-ST as an unrelated globular protein
presumed to lack inherent biological activity may here serve as an al-
ternative approach to estimate passive tissue accumulation related to
the size of a probe before and after the induced cell death.
We propose that the decreased retention of [11C]-mTrx-GFP-ST re-
veals therapy-induced changes in the tissue environment that will
also affect the uptake and retention of [11C]-AnxA5-ST and thus the
therapeutic read-outs obtained with the tracer. Although increases in
hepatic AnxA5 uptake revealed the robust anti-Fas induced apoptosis,
the corresponding decrease in uptake of the control tracer suggeststhat comparisons of AnxA5treat versus AnxA5baseline may underestimate
the effect. If ﬂow and permeability conditions in the tissue and effects
on these caused by the therapy are not investigated, small changes
may be missed entirely [57]. We therefore propose and have recently
further demonstrated [32] that PET imaging based on AnxA5 as a tracer
can beneﬁt from including imaging with a size-matched inactive
control to examine these ﬂow and permeability effects on probe de-
livery and retention, at least when validating the method for new
therapeutics.
Radioactivity levels in the kidney of the anti-Fas treated animals
decreased for both [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST compared
to pre-treatment levels. Similar decreases in the renal uptake of 99mTc-
HYNIC-annexin V have previously been observed and were suggested
to be due to the markedly increased number of binding sites in the
apoptotic liver, leading to compartmentalization effects and decreased
binding in kidney [47].
In addition to facilitating repeated imaging, a short-lived radionu-
clide should reduce radiation doses to the subject, all other factors
being equal. To our knowledge, the Sel-tag is the only technique
that allows mild, site-speciﬁc labeling of proteins with such short-
lived radionuclides as 11C. The highly nucleophilic Sec of the Sel-tag
has been shown to improve radiolabeling even when compared to
that of other closely-related tags [16]. That our 11C-labeling of
AnxA5 was Sec-mediated is also supported by previous attempts to
label unmodiﬁed AnxA5 using [11C]methyl iodide [58], which was
only accomplished in low yields when the protein was heated to
80 °C, at which temperature it is denatured. The Sel-tag is necessarily
inserted at the C-terminus due to the methodology for its production
[18] and was shown here to not adversely affect AnA5 functionality in
cell culture or in vivo. Crystal structure determinations show that
both the C- and N-terminus are on the opposite side of the AnxA5
molecule, away from the membrane-binding region [30]. Therefore,
labeling at either the C- or N-terminus interfere minimally with the
protein binding to PS at target membranes, which was corroborated
here by in vitro cell binding and ﬂow cytometry analyses and is also
supported by the similar sensitivities of [11C]-AnxA5-ST and the
N-terminus labeled V-128 in detecting hepatic cell death [45].
A major reason that proteins are not yet widely used in functional
PET imaging is the lack of suitable labeling procedures [15]. A proto-
col for Sel-tagging proteins along with discussions of potential pitfalls
and probable solutions has been previously published [17]. The spe-
ciﬁcs for using it to label AnxA5 and its size-matched control are
given here. The technology can be used for virtually any protein
that can be expressed in E. coli, as long as biological activity is unaf-
fected by C-terminus modiﬁcation and DTT reduction [17]. Although
short-lived radionuclides have speciﬁc advantages in enabling re-
peated imaging within hours, the labeling technique is not restricted
to use with 11C. In fact it has already been utilized for labeling with
68Ga via a thiol-reactive precursor [19] and is currently also being
extended to labeling with 18F. In this way, the same tagging method
can be used for rapid multi-probe assays with 11C during the drug de-
velopment phase as well as in subsequent, high-throughput imple-
mentations with the more long-lived radiotracers.
5. Conclusions
Our results illustrate the feasibility of studying cell death through
multi-tracer imaging strategies utilizing 11C-labeled Sel-tagged pro-
teins. Comparing the uptake of AnxA5 with a size-matched control
and using dynamic imaging protocols were important for revealing
factors contributing to normal and therapy-induced uptake patterns.
We conclude that 11C-labeled Sel-tagged AnxA5 is a promising new
biomarker for PET imaging of cell death and combining it with assess-
ments of co-variations in ﬂow and permeability may provide a solid
foundation for sensitive assessments of therapy-induced cell death
in vivo.
Fig. 8. PET imaging of liver apoptosis using [11C]-AnxA5-ST. (A) Representative MIP image of radioactivity summed over 60 min after tail vein injection of [11C]-AnxA5-ST at baseline
before (left) and 3 h after (right) i.v. injection of anti-Fas antibodies in the same mouse. (B) Time activity curves for the radioactivity from injection of [11C]-AnxA5-ST in the liver at
baseline (triangles) or 3 h after anti-Fas treatment (squares). Curves are means±SD for two animals imaged simultaneously in paired baseline and anti-fas studies. (C) Logan plots
showing changes in distribution volume for [11C]-AnxA5-ST in liver before (dashed line) or after anti-Fas treatment (solid line). (D) IHC analyses of active caspase-3 in liver before
(top) or after treatment with anti-Fas antibodies (bottom). (E–G) Corresponding PET experiments with [11C]-mTrx-GFP-ST reveal instead a decrease in liver uptake of the
size-matched control protein after anti-Fas treatment.
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